Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register by Symmons, Deborah PM & Silman, Alan J
Page 1 of 6
(page number not for citation purposes)
Available online http://arthritis-research.com/content/8/4/214
Abstract
Over 3500 patients with recent onset inflammatory polyarthritis (IP)
have been recruited by the Norfolk Arthritis Register (NOAR) since
1990. Longitudinal data from this cohort have been used to examine
the prevalence and predictors of remission, functional disability,
radiological outcome, cardiovascular mortality and co-morbidity
and the development of non-Hodgkin’s lymphoma. Rheumatoid
factor titre, high baseline C-reactive protein and high baseline
HAQ score are all predictors of a poor outcome. There is a strong
association between possession of the shared epitope and the
development of erosions. Patients who satisfy the American
College of Rheumatology criteria for rheumatoid arthritis (RA) have
a worse prognosis than those who do not. However, it appears
that these patients are a poorly defined subset of all those with IP
rather than having an entirely separate disease entity. New statis-
tical techniques offer exciting possibilities for using longitudinal
datasets such as NOAR to explore the long-term effects of
treatment in IP and RA.
Introduction
The Norfolk Arthritis Register (NOAR) was established during
1989. By the beginning of 1990, all the general practitioners
in what was then the Norwich Health Authority had been
visited and asked to participate. From 1 January 1990, the
general practitioners and local rheumatologists referred to
NOAR all adults (aged ≥16) whom they saw with two or more
swollen joints, lasting for 4 weeks or more, with an onset of
symptoms after 1 January 1989.
After receiving a notification, NOAR sends one of its team of
metrologists (research nurses) to the patient’s home to take a
standardised history and to examine the joints for tenderness,
swelling and deformity/damage [1]. In addition, a blood
sample is taken for rheumatoid factor (RF) measurement and
for DNA extraction. Serum is also stored. The patient
completes a Health Assessment Questionnaire (HAQ) [2]
adapted for British use [3].
Over 3,500 patients have now been recruited by NOAR.
Although the 15 years since NOAR was established have
seen dramatic changes in the range of disease-modifying
antirheumatic drugs (DMARDS) that are available and the
way in which they are used, one of the fundamental questions
that NOAR was set up to address remains highly pertinent.
This is the question of whether it is possible to predict, early
in the course of the disease, a patient’s natural history.
This question becomes ever more relevant as it is now well
accepted that patients who are destined to have persistent
disabling arthritis should start DMARD therapy as soon as
possible (preferably within the first 12 weeks of disease).
Patients who fail to respond to DMARD therapy should be
moved on to a biologic agent. Set against this is the fact that
many patients with recent-onset arthritis do well. In some
patients, the arthritis resolves completely and many patients
never develop any significant disability or radiological
erosions. It would be exposing these patients to unnecessary
risk to give them intensive DMARD therapy or even biologic
therapy. On the other hand, some patients do very badly and
fail to respond to one DMARD after another. It would clearly
be useful to be able to predict both a poor prognosis and
response to individual agents so that the right drug can be
given to the right patient — ‘designer therapy’.
Predictors (or determinants) of outcome can be grouped into
person-specific factors — age, gender, socioeconomic status,
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lifestyle (e.g. smoking, exercise, alcohol, diet), psychological
factors (e.g. coping strategies), genetic make-up — disease-
specific factors (e.g. severity of arthritis, comorbidity) and
treatment-specific factors (e.g. drug and nondrug modalities,
adverse events, patient adherence to prescribed treatment).
All these factors interact and the prediction of outcome for
the individual patient (as opposed to the average patient)
remains problematic.
Classification of inflammatory polyarthritis
and rheumatoid arthritis
When NOAR was initially established, its aim was to study
the natural history of rheumatoid arthritis (RA). The net was
deliberately cast wide at the time of recruitment as it was
always clear that patients would not satisfy classification
criteria for RA within a few days or weeks of developing
arthritis. NOAR was established fairly soon after the
publication of the 1987 American Rheumatism Association,
now the American College of Rheumatology (ACR), criteria
for RA [4]. In the early years, therefore, NOAR investigators
as well as others were learning the strengths and
weaknesses of these criteria (which had been derived
predominantly from current attenders to tertiary care with
long-standing disease).
One finding was that the criteria were not robust — patients
might satisfy the criteria on one visit and not on another. We
decided that the appropriate method was to apply the criteria
cumulatively. It took many patients up to 5 years to satisfy the
criteria [5]. What is more, there was no clear division
between those patients who did satisfy the ACR criteria and
those patients who did not satisfy the criteria with regards to
their ultimate prognosis. While those who satisfied the criteria
— and particularly those who were RF-positive — tended to
have a worse prognosis, many patients who did not satisfy
the criteria also had a poor outcome. We have therefore
tended increasingly to report the results of our whole
inflammatory polyarthritis (IP) cohort and then to present,
separately, the outcome of those patients who can be
classified as having RA. We feel that this is more informative
and also that this is a more generalisable cohort in whom to
develop prognostic models.
The time is probably now right to reconsider whether
classification criteria for ‘early RA’ can be developed. It does
appear that IP patients with autoantibodies (either RF or
anticyclic citrullinated peptide (anti-CCP) antibodies) may
have a different aetiology and a different response to
treatment from patients who are autoantibody negative [6,7].
It may therefore be more helpful in future to separate these
two groups rather than to leave them combined in the single
entity of IP. There is a tendency always to focus on the
subgroup of patients with the worst prognosis (e.g. those
who satisfy the ACR criteria or those who are autoantibody-
positive). It is important to emphasise, however, that even
those patients in the better prognosis group may have a poor
outcome with regards to disability and deformity. It is possible
that none of the current DMARDs or perhaps even the
biologic agents are effective in the better prognosis group
and that we have to start from scratch in establishing the best
way of managing patients with mild disease.
Outcome following the onset of inflammatory
polyarthritis
NOAR dataset has been used to address questions about
the occurrence of a variety of outcomes at 1 year, 3 years,
5 years and now 10 years, as well as predictors of these
outcomes [8]
Remission
It is important to be able to predict which patients will go into
remission; that is, which patients will have no evidence of any
inflammatory activity in their joints while they are off treatment.
Persistence is the opposite of remission. There are problems
in the literature regarding the definition of remission and the
resolution of IP. Both require a robust method of measuring
disease activity.
The first systematic approach to the definition of remission in
RA was carried out on behalf of the American Rheumatism
Association in 1981 [9]. The development of the disease
activity score (DAS) [10] and its daughter (DAS-28) [11] has
more recently helped to clarify the situation. Van Gestel and
colleagues assessed patients both with a DAS-28 and with
the American Rheumatism Association remission criteria, and
estimated that a DAS-28 less than 2.6 could be regarded as
remission [12].
In NOAR, however, we began to look at remission before the
publication of the DAS-28 work. We therefore developed our
own definition of ‘remission off treatment’, being no soft
tissue joint swelling and the patient not having been treated
with DMARDs or steroids within the previous 3 months.
‘Treatment-induced remission’ had the same definition except
that patients could be receiving DMARDs. At 3 years, 32% of
NOAR IP patients were in remission, as were 18% of NOAR
patients in the RA subgroup [8]. Only 11% of the IP patients
were in remission at 1 year, 2 years and 3 years, and so could
be regarded as being in complete resolution of their disease.
In a multiple logistic regression analysis, three baseline
variables (RF negativity, fewer than six tender joints and the
absence of ankle swelling) were found to be important
independent predictors of remission. The model only had an
explained variance of 17%, however, and clearly could not be
used in the routine clinical setting [8].
It is possible that the patient’s production of endogenous
corticosteroids may influence IP persistence. Individuals who
produce high levels of endogenous steroid may ‘switch off’
their arthritis, whereas those whose steroid production is
lower may have persistent disease. This level of response is
probably genetically determined. The early administration ofPage 3 of 6
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intraarticular or intramuscular steroids in this very early phase
may be of lasting benefit [13].
We then focused on trying to predict those individuals who
would have a poor outcome. It is important to emphasise,
however, that many patients who did not go into complete
remission nevertheless had a relatively good outcome.
Functional disability
Functional disability measured using the HAQ has proved to
be one of the most reliable outcome measures for both IP
and RA. Many researchers have found that the HAQ score
predicts many features of the patient’s subsequent disease
course, including mortality [14]. Patients in NOAR complete a
HAQ at baseline and at years 1, 2, 3, 4, 5, 7, 10, 12 and 15.
The proportion of patients with a HAQ score ≥1.0 continues
to rise as time goes by, from 29% at 1 year, 44% at 3 years,
47% at 5 years to 49% at 10 years. Most of the disability
accrues in the first 3 years — but it has to be remembered that
the HAQ score can only be measured in survivors, and the
most disabled patients are more likely to die or be lost to
follow-up.
We have found that the 1-year HAQ score is a better
predictor of subsequent outcome than the baseline HAQ
score [15]. This offers hope for the early modification of what
might otherwise have been a poor outcome. The key risk
factors for the development of moderate disability (HAQ
score  ≥1.0) at 5 years are being female, aged over 64 at
baseline, the number of damaged joints, RF positivity and the
presence of nodules at baseline [16] A similar set of variables
had been found to predict a HAQ score >1.0 at 3 years [8].
Radiological outcome
The rules for conducting X-ray scans in NOAR have varied
over the course of the past 15 years. X-rays were initially not
carried out at baseline. The assumption at that time was that
patients would be presenting early, before erosions could
have developed, and it would therefore be unethical to
expose them to radiation. As the register grew, however,
patients had longer in which to present (the requirement to
have an onset since 1 January 1989 has only recently been
moved forward to 1 January 2000). X-rays were initially
performed in NOAR at the first and/or second anniversary of
presentation if a patient already satisfied the ACR criteria for
RA, or if the presence of erosions would lead the patient to
satisfy these criteria. All patients were X-rayed at the fifth
anniversary of presentation.
More recently we have performed baseline X-ray scans in a
series of patients presenting from 2000 onwards. We there-
fore have some information about predictors of erosions at
presentation and 1 year, 3 years and 5 years after symptom
onset. Erosions are much more common at baseline in older
patients than in younger patients [17]. We were able to show
that, although the peak incidence of first erosions is within the
first 24 months of disease, individuals who are nonerosive at
24 months have an ongoing risk of becoming erosive, which
does not decline with time [18].
The baseline C-reactive protein (CRP) level was a strong
predictor of the degree of erosive damage on both the 1-year
and 5-year anniversary films. An RF titre greater than 1 in 160
was the strongest predictor of X-ray progression [19].
There has been much recent interest in the role of anti-CCP
autoantibodies in predicting outcome in RA and IP. Anti-CCP
antibodies are present in around 55% of patients with early
RA and have been found to predict the development and
progression of erosions within the first 2 years of disease
[20]. Anti-CCP antibodies are much more specific for RA
than RF. We found the predictive value of anti-CCP
antibodies, measured using a second-generation ELISA
assay, in 198 individuals with radiographs of their hands and
feet taken within 12 months of symptom onset to be higher
than the predictive value of RF with respect to both the
development and progression of erosions [21]. The measure-
ment of anti-CCP antibodies appeared to be particularly
useful as a predictor of radiological outcome in those who are
RF-negative.
Cardiovascular mortality and comorbidity
There is increasing interest in the literature regarding the link
between inflammatory musculoskeletal conditions and
accelerated atherosclerosis. This link is evident even in IP
patients in the early years of disease. Among the first 1,235
subjects recruited to NOAR up to the end of 1994 and
followed for a median of 8 years, the standardised mortality
ratios in RF-positive patients were 1.5 for men and 1.4 for
women. All the excess deaths in seropositive women were
due to cardiovascular causes. The standardised mortality
ratio for cardiovascular mortality in this group of women was
2.0 (95% confidence interval, 1.2–3.3) [22].
The baseline CRP level was a strong predictor of future
cardiovascular mortality, thus supporting the hypothesis that
the increased risk of coronary heart disease in RA and IP is
related to the burden of inflammation [23]. Perhaps surpri-
singly, smoking — either ever or current — was not a predictor
of cardiovascular mortality, but this might reflect the dominant
effect of the inflammation in this population. Although based
on cross-sectional data, we have also noted that the
prevalence of angina as detected by the Rose angina
questionnaire increases with disease duration [24].
Non-Hodgkin’s lymphoma
Although there was no evidence of any overall increased risk
of cancer in the early years of IP and RA in NOAR, there was
a definite increased risk of developing non-Hodgkin’s
lymphoma (standardised incidence ratio, 2.4; 95% confi-
dence interval, 1.2–4.2). The standardised incidence ratio
was even higher in the subset of patients with RA (2.9; 95%
Available online http://arthritis-research.com/content/8/4/214confidence interval, 1.3–5.6). Predictors of developing non-
Hodgkin’s lymphoma included RF, HAQ score ≥1 and the
presence of erosions [25].
Response to treatment
It is clear that outcome in an observational cohort such as
NOAR is related in part to the treatment received.
Understanding the role of laboratory or clinical predictors in
explaining outcome requires adjustment for the probable
phenomenon that the more severe the disease, the more
intensive the therapy. The question can conversely be turned
on its head, and the data can be used to address questions
of treatment efficacy. It is difficult to explore the effects of
treatment in longitudinal observational cohorts such as
NOAR because, as implied earlier, the decision to treat is not
random. Unless the treatment is so effective as to negate all
the effects of disease severity, then those patients who are
treated are likely to have a worse outcome than those whose
disease was so mild as not to warrant therapy.
The propensity score and marginal structural modelling offer
two ways of adjusting for the baseline severity, which
influences the physician’s decision to start treatment. We have
used the propensity score method to demonstrate the benefit
of starting treatment within 6 months of symptom onset on
functional outcome [26] and on radiological outcome [27].
With the advent of new treatment strategies and more
effective (but also expensive) treatments, it becomes ever
more important to try and predict whether or not a patient will
respond to a particular medication. There are a number of
variables that may influence treatment response. These
include genetic factors, both genes that affect the severity of
the disease and genes that affect the handling of the drug.
Then there are psychosocial factors such as adherence to
and expectations of therapy outcome. Finally, there are
aspects related to the underlying disease and associated
comorbidities. Those patients who are RF-positive or are
shared epitope (SE)-positive may be more or less likely to
response to certain DMARDs.
We found that it was not possible to predict the response to
methotrexate (defined as remaining on the drug with no
additional DMARD starts at 1 year) with any useful degree of
accuracy using baseline clinical and demographic variables
[28]. The only predictor of discontinuing methotrexate was a
high baseline HAQ score. Work is now focusing on
identifying genetic predictors of response by looking at
various genes along the metabolic pathway of methotrexate.
Genetic predictors of outcome
We have had only limited success in predicting outcome
robustly from routinely collected clinical and laboratory
variables. It seems probable that constitutional predictors
such as genetic factors play an important role, and they are
therefore an obvious target to study.
It is well recognised that the region of HLADRB1 known as
the SE is the strongest genetic predictor of outcome in RA. In
NOAR, we found no evidence that the SE (or any particular
SE-bearing allele) had any influence on disease remission or
persistence. There was a weak influence of the SE on the
development of moderate disability (HAQ score >1.0)
confined to individuals who were RF-negative. The association
between the SE and the development of radiological erosions
was much stronger. In particular, individuals who were
homozygous for HLADRB1*0404 were four times more likely
to develop erosions than those who were SE-negative (odds
ratio, 4.2; 95% confidence interval, 2.0–88.5) [29].
NOAR patients who were homozygous for the SE similarly
had increased all-cause mortality and cardiovascular mortality
over the first 8 years of disease [30].
No association was found between individual polymorphisms
of the tumour necrosis factor gene [31] or the mannose
binding lectin gene [32] and the development of radiological
erosions at 5 years.
Citrullination, the process underlying the development of anti-
CCP antibodies, is mediated by the enzyme peptidylarginine
deiminase — of which there are five isoforms. A Japanese group
reported an association between the PADI4 gene and RA [33].
We were not able, however, to find any association between
polymorphisms of the PADI4 gene and the presence, the
extent or the progression of erosions or the development of
anti-CCP antibodies [34]. Further publications have confirmed
an association between PADI4 and RA in another Japanese
population [35], in a South Korean population [36] and in a
North America population [37], but not in a French population
[38] or a Swedish population [37]. This may reflect different
genetic associations in different ethnic groups.
Conclusion
Certain predictors recur as we look at a variety of outcomes.
These include RF positivity, a high baseline CRP and a high
baseline HAQ score. With regards to the CRP and HAQ, it
seems probable that the baseline values are important
predictors of the later course of the disease because they are
surrogates for the cumulative disease activity and disease
severity. Those patients whose disease starts badly tend to
continue to do badly. We have shown the benefits of starting
disease-modifying therapy early in the course of the disease.
The fact that a greater proportion of patients are now treated
early and with more effective treatment combinations and
regimes leads us to hope that we will find the 5-year outcome
of patients with an onset of disease since 2000 to be better
than that in those patients with an onset in 1990. However,
some patients continue to present late to medical care and
not all patients respond even to the most modern and
aggressive of regimes. It is important, therefore, to continue
to enrol and study patients so that we can understand more
about this disabling disease, which shortens life expectancy.
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